Thrombosis and haemostasis

publication venue for

High frequency of premature termination mutations in the factor V gene: three factor V deficiency case reports and a mutation review. 2005
Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial.. 119. 2019
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.. 118. 2018
Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).. 118. 2018
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.. 117. 2017
Identification of unique venous thromboembolism-susceptibility variants in African-Americans.. 117. 2017
D-dimer and the Risk of Stroke and Coronary Heart Disease. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.. 117. 2016
Circulating protein Z concentration, PROZ variants, and unexplained cerebral infarction in young and middle-aged adults.. 117. 2016
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice.. 114. 2015
Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.. 113. 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.. 111. 2014
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.. 110. 2013
Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity.. 109. 2013
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.. 104. 2010
Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.. 104. 2010
Human solCD39 inhibits injury-induced development of neointimal hyperplasia.. 103. 2009
Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.. 100. 2008
Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix.. 96. 2006
ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.. 95. 2006
Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.. 95. 2006
Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration.. 92. 2004
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.. 91. 2004
Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF).. 88. 2002
Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin.. 87. 2002
Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies.. 86. 2001
Human atheromatous plaque extracts induce tissue factor activity (TFa) in monocytes and also express constitutive TFa.. 81. 1999
Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells.. 79. 1998
Fibrillin containing elastic microfibrils support platelet adhesion under dynamic shear conditions.. 79. 1998
Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog.. 74. 1995
Relationships between haemostatic factors and capillary morphology in human diabetic neuropathy.. 68. 1992
The hemodynamic and fibrinolytic response to low dose epinephrine and phenylephrine infusions during total hip replacement under epidural anesthesia.. 68. 1992
Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells.. 56. 1986
Plasma and platelet fibrinogen differ in gamma chain content.. 51. 1984
Prevention of intravascular thrombus formation on plastic catheters with heparin-benzalkonium complex: in vivo and in vitro studies.. 41. 1979
Role of immunologic arterial injury in atherogenesis.. 39. 1978
The platelet-endothelial cell--VIII axis.. 35. 1976
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.. 112. 2014
Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis.. 75. 1996
Another interaction of the FcR system with IVIG. 2002
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. 2019
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. 2004
A possible solution to the paradox of the "lupus anticoagulant": antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin-V. 1999
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).. 105. 2011
Outcome studies of pulmonary embolism versus accuracy: they do not equate.. 96. 2006
Optimizing initial therapy of acute venous thromboembolism.. 90. 2003
The role of thrombin and protease-activated receptors in pain mechanisms. 2010
Role of c-kit/Kit ligand signaling in regulating vasculogenesis. 2003
Ubiquitylation within signaling pathways in- and outside of inflammation. 2007
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 2004
Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. 1999
The significance of subendothelial von Willebrand factor. 1997
Cellular receptors in the regulation of plasmin generation. 1995
Fetal neonatal thrombocytopenia. 1995
Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. 1995
Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH. 1991
Acquired von Willebrand syndrome: data from an international registry. 2000

VIVO Weill Cornell Medical College

Thrombosis and haemostasis Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)